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controls based on age, gender, and hospital region. RESULTS: The 2006 NIS con-
tained a total of 15,748 unweighted hospital inpatient stays with pulmonary surgery, 
2,412 of which included an air leak and 13,336 were non-air leak stays. Patients with 
pulmonary surgery stays including an air leak were older than those patients without 
an air leak (61.5 yrs vs. 60.2 yrs; p = 0.0002), were less likely to be from the Northeast 
(17.3% vs. 21.52%, p < 0.0001) and more likely to be from the South (44.9% vs. 
41.9%, p = 0.0010). Multivariate regressions (N = 15,748) yielded incremental LOS, 
total charges and odds of in-hospital mortality due to the presence of an air leak of 
3.5 days (SE = 0.15), $14,272 ($1,198.2), and +26.0% (95% CI:-0.34%, 64.2%), 
respectively. The 1:1 case-control matching approach (N = 2,364 matched pairs) 
yielded differences in LOS, total charges and odds of in-hospital mortality of 3.6 days 
(0.14), $14,011 ($1,207.8) and +17.2% (−0.17%, 66.2%), respectively. CONCLU-
SIONS: In evaluating differences in health outcomes in a U.S. hospital inpatient 
database, adjusting for covariates using a matching scheme yielded only a modest 
impact vs. multivariate regression analysis.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
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OBJECTIVES: Compare two different formats—checklist and open text— of ques-
tions soliciting opioid-related side effects (OSEs) with respect to the proportion of 
patients reporting OSEs and the number of OSEs reported. METHODS: Data from 
Day 3 assessment of the oxycodone IR users registry (OUR), an ongoing, prospective, 
multicenter registry of patients age 18–85 with acute episodes of non-malignant pain 
requiring treatment with oxycodone IR for >5 days were used. Patients who completed 
two types of OSEs assessments on Day3 were included in the analysis. The ﬁrst assess-
ment is in an open-text format allowing for identiﬁcation of up to 7 symptoms. The 
second is in a checklist format listing 14 symptoms along with questions about the 
frequency and degree of distress associated with each. Correspondences between 
patient responses solicited through the two different formats were examined using 
descriptive statistics. Interim data were used for the current analysis. The entire registry 
patient population will be analyzed in early 2010. RESULTS: Among 182 patients 
examined for this analysis, mean (±SD) age was 49.3 (±12.7) years, 60.2% were female 
and 74.3% white. Oxycodone IR was most commonly prescribed for injury/trauma 
(30.5%), back/neck pain (28.8%), and arthritis (18.1%). The proportion of patients 
reporting any OSEs in the checklist was nearly two-fold that in the open text (98.9 
vs 53.6%; p < 0.001). Patients, on average, reported 4.1 (SD = 6.3) OSEs on the 
checklist vs 1.3 (SD = 1.6) on the open-text question (p < 0.001). Signiﬁcantly more 
events were reported in the checklist vs open text question for each OSE examined (p 
< 0.001). OSEs reported to be frequent and bothersome on the checklist were signiﬁ-
cantly more likely to appear in the open text compared to infrequent and mild 
symptoms. CONCLUSIONS: Frequency and extent of OSE reporting may vary by the 
format of questions administered. Caution is warranted in collecting, reporting, and 
comparing symptom data from different studies.
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OBJECTIVES: To determine the independent predictors of prescription of anti-obesity 
medication for adult patients diagnosed with obesity and to determine association of 
insurance status on anti-obesity medication prescription. METHODS: The data source 
was 2006 and 2007 National Ambulatory Medical Care Survey, a national survey of 
U.S. non-institutionalized population. All adult patients >= 18 years diagnosed with 
obesity (ICD-9-CM: 278.00) were included in the study for analysis. Weighted descrip-
tive analysis and multivariate logistic regression were carried out to identify patterns 
of drug use and independent predictors of at least one prescription of anti-obesity 
medication, adjusting for age, race, sex, region, insurance status, co-morbidity, coun-
seling and MSA. RESULTS: An estimated 113 million adult visits had diagnosis of 
obesity in the 2 years. Of these, 5.79% visits resulted in anti-obesity medication 
prescription. In multivariate model, males (OR—0.244 CI: 0.128–0.463), were less 
likely to receive anti-obesity medication prescription as compared to females. Patient 
visits covered by private or public insurance were less likely to receive prescription 
(OR—0.056 CI: 0.021–0.146 and OR—0.080 CI: 0.034–0.189 respectively). Increase 
in age was associated with decreased (OR—0.976 CI: 0.962–0.990) likelihood of 
receiving anti-obesity medication prescription. Adults who received obesity counseling 
were almost four times more likely to receive anti-obesity medication prescription 
(OR—3.730 CI: 1.878–7.407). Physician type, MSA, co-morbidity status, race and 
region were not signiﬁcantly associated in the ﬁnal multivariate model. CONCLU-
SIONS: Study ﬁnding suggests that adequate coverage for anti-obesity medications 
might not be available for obese adults. Obesity is a harbinger for other chronic 
diseases like CHF, diabetes, hypertension, arthritis and some cancers; thus reducing 
access to obesity medications might lead to an overall increase in the health care 
expenditure in United States. Obesity counseling seems to promote medication use 
which might be due to an increased awareness among obese patients.
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OBJECTIVES: Patients with hemophilia require frequent administration of intrave-
nous clotting factor to prophylactically or episodically control bleeding from injury 
or activity. Severe patients may require the placement of a central venous access device 
due to the frequency of infusions or poor peripheral venous access. Subsequent central 
venous line infections are potentially life threatening and may require hospitalization 
which consumes excessive health care resources. Catheter infection events cost up to 
$29,000 per episode for acutely ill patients and can be much higher when cost of 
clotting factor is included. Costs of these events include intravenous antibiotics and 
device replacement. The study purpose was to evaluate incidence of central venous 
access device infections in people receiving clotting factor in the home setting. 
METHODS: A retrospective, longitudinal analysis of patients receiving intravenous 
clotting factor using data from the Accredo electronic medical record was conducted. 
Inclusion criteria were the presence or placement of a central venous access device and 
the dispensing of at least one clotting factor prescription during the study period. 
Patients were followed from October 1, 2008 through September 30, 2009. The 
patient reported infection rate was deﬁned as the number of bloodstream infections 
per 1000 patient catheter days. RESULTS: The sample size of 475 patients reviewed 
encompassed 131,916 patient catheter days during the study period with average 
catheter dwell time of 278 days. The central line infection rate was 0.53 per 1000 
patient catheter days with minimal month to month variation. CONCLUSIONS: 
Intravenous administration of clotting factor via a central venous access device is an 
important alternative infusion option for select patients with bleeding disorders. 
Patients can be well managed in the home on intravenously administered factor via 
central venous access devices. This is an important contribution to limited literature 
on central line infections in the home setting.
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OBJECTIVES: This study assessed the daily average consumption (DACON) patterns 
for oxymorphone extended release tablets and oxycodone hydrochloride controlled 
release tablets in the treatment of low back pain (LBP) and osteoarthritis (OA). 
METHODS: Observational, retrospective study of a US commercially insured health 
plan cohort, which included pharmacy and medical claims for patients with ≥1 diag-
nosis of LBP and/or OA. Subjects with OA and or LBP were identiﬁed by ICD-9-CM 
codes following classiﬁcations1,2,3 previously employed. The primary outcome measure 
for the analysis was DACON which was calculated by dividing the total number of 
tablets dispensed by the total number of days supply for equianalgesic4 doses of each 
medication, as deﬁned by an oxymorphone ER : oxycodone HCl CR ratio of 1:2. 
Patient demographic data were assessed and outcomes were stratiﬁed by age, gender, 
and region comparing users who had claim activity for 2 or more of the two medica-
tions for at least 30 days prior to and 90 days after the index date. The t-test was 
used to compare mean differences between the two populations for continuous vari-
ables. Multivariate analysis was conducted as a sensitivity analysis in controlling for 
age, gender, and region heterogeneity. RESULTS: Data analyzed encompassed 
approximately 25 million covered lives for the period January 2006 to March 2009. 
DACON across all tablet strengths for oxymorphone ER was 2.2 compared to 2.6 
for oxycodone CR (p < 0.01). For each formulations maximum strength tablet, oxy-
morphone ER 40 mg DACON was 2.6, compared to 3.7 for oxycodone CR 80 mg 
(p < 0.01). All statistically signiﬁcant results for patients with LBP and/or OA had 
higher DACONs for oxycodone CR than for oxymorphone ER. CONCLUSIONS: 
These ﬁndings imply that health plan drug policies may need to take into consideration 
overall usage patterns, patient demographics, and medical diagnoses for long-acting 
opioids in addition to tablet costs when making formulary decisions.
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OBJECTIVES: The aim of this study was to conduct a meta-analysis of randomized 
clinical trials (RCTs) to determine effectiveness and safety of parecoxib as an analgesic 
option for adult patients in orthopedics surgery. METHODS: All meta-analysis esti-
mations were performed with RCTs based on trials with similar parecoxib doses (20 
or 40 mg) and by type of comparator (placebo or other drugs). Effectiveness was 
assessed with patient global treatment evaluation, consuming rescue drug rate, pain 
intensity at 24 or 48 h after surgery and morphine consume after surgery; safety with 
the frequency and type of adverse events(AE). RCT were searched in December 2008 
